Search clinical trials for: Rituximab

Total 3078 results

Merck KGaA, Darmstadt, Germany

Completed

Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer (BALI-1)

Breast Neoplasm

Spain, United Kingdom, Germany, Australia, Austria, Belgium, Israel, New Zealand, Portugal, Italy, Ireland
National Taiwan University Hospital
Chang Gung Memorial Hospital; Taipei Veterans General Hospital, Taiwan; Tri-Service... and other collaborators

Completed

Cetuximab Plus P-HDFL for the First-line Treatment of Advanced Gastric Cancer (FLAG)

Gastric Cancer

Taiwan
Centre Oscar Lambret

Completed

Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery

Head and Neck Cancer

France
Wugen, Inc.

Not yet recruiting

A Phase 1b Study of WU-NK-101 in Combination With Cetuximab

Squamous Cell Carcinoma of Head and Neck | Colorectal Cancer Metastatic
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Refractory Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma

United States
Enterome

Recruiting

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (SIDNEY)

Follicular Lymphoma | Marginal Zone Lymphoma

United States, Italy, Spain
Assistance Publique - Hôpitaux de Paris
French Vasculitis Study Group

Active, not recruiting

Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. (MAINRITSEG)

Eosinophilic Granulomatosis With Polyangiitis

France
First Affiliated Hospital, Sun Yat-Sen University
Second Affiliated Hospital of Guangzhou Medical University

Unknown

Effect of BM-MSCs on Chronic AMR After Kidney Transplantation

Kidney Transplantation

China
AZ-VUB

Unknown

Long-term Function of Beta Cell Allografts in Non-uremic Type 1 Diabetic Patients

Diabetes Mellitus, Type 1

Belgium
Grupo Oncológico para el Tratamiento y el Estudio...

Unknown

Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line

Follicular Non-Hodgking´s Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line.

Spain
Gustave Roussy, Cancer Campus, Grand Paris
Merck Serono International SA

Completed

Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin

Advanced Biliary Cancer

France
Bristol-Myers Squibb

Completed

BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies

Colorectal Cancer

United States, Canada, Netherlands
University of Rochester

Withdrawn

Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease

Active Chronic Graft Versus Host Disease

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Active, not recruiting

Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

Head and Neck Cancer

United States, Canada, Saudi Arabia, China
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

Metastatic Colorectal Cancer | Squamous Cell Carcinoma of Head and Neck (SCCHN)

France, Belgium, Spain, Germany, Italy, Canada, United States
Roswell Park Cancer Institute

Terminated

Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer

Head and Neck Cancer

United States
University of Alabama at Birmingham
National Cancer Institute (NCI)

Terminated

Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx

Head and Neck Cancer

United States
Spanish Cooperative Group for the Treatment of...

Completed

Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours (MACRO-2)

Metastatic Colorectal Cancer

Spain
Scripps Health

Recruiting

Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia

Hairy Cell Leukemia

United States
Incyte Corporation

Active, not recruiting

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)

Follicular Lymphoma | Marginal Zone Lymphoma

Finland, United States, Spain, Korea, Republic of, Canada, Israel, Turkey, United Kingdom, Netherlands, Greece, Italy, France, Taiwan, Germany, Belgium, Japan, Czechia, Switzerland, Ireland, Poland, Ukraine, Australia, Denmark, Hungary, Swede... and more
Pharmatech
Cephalon

Completed

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (904)

Diffuse Large B-Cell Lymphoma

United States
University of Alabama at Birmingham
National Cancer Institute (NCI); Biogen

Completed

Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma

United States
National Cancer Institute (NCI)

Terminated

17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent Burkitt Lymphoma | AIDS-Related Burkitt Lymphoma | Atypical Burkitt/Burkitt-Like Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2... and other conditions

United States
University of Nebraska
Schering-Plough

Completed

CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma

Non-Hodgkins Lymphoma

United States
University of Göttingen
Roche Pharma AG; Mundipharma Research GmbH & Co KG

Completed

Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma (B-R-ENDA)

Aggressive Lymphoma

Germany
Pfizer
UCB Pharma

Completed

Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell

United States, France, United Kingdom, Singapore, Korea, Republic of, Germany
Astellas Pharma Europe B.V.

Completed

Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia (NORMA)

Chronic Lymphocytic Leukemia

Russian Federation
Astellas Pharma Europe B.V.

Completed

Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin

Russian Federation
Zhejiang Cancer Hospital

Recruiting

A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory

China
Asan Medical Center
Cheolwon Suh

Recruiting

Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma (PTLD)

Diffuse Large B Cell Lymphoma

Korea, Republic of
Innovent Biologics (Suzhou) Co. Ltd.

Withdrawn

Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma

Follicular Lymphoma

China
Sun Yat-sen University

Completed

Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL

Lymphoma, Large B-Cell, Diffuse

China
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Groupe Oncologie Radiotherapie Tete et Cou

Recruiting

Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer (XXL_2022-01)

Squamous Cell Carcinoma of the Head and Neck

France
NCIC Clinical Trials Group

Completed

Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer

Colorectal Cancer

Canada
UNC Lineberger Comprehensive Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); National Center for Research... and other collaborators

Completed

Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer

Breast Cancer

United States
Central European Cooperative Oncology Group

Completed

Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer (CORE 2)

Colorectal Cancer

Israel, Austria, Croatia, Greece, Serbia, Bosnia and Herzegovina, Bulgaria, Estonia, Hungary, Latvia, Romania, Slovakia, Slovenia
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Stage III or Stage IV Head and Neck Cancer

Head and Neck Cancer

United States
Eye & ENT Hospital of Fudan University

Recruiting

Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN

Head and Neck Neoplasms | Metastatic Cancer | Recurrent Disease

China
Bayer

Completed

Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination

Neoplasms

United States
Helse Fonna

Completed

Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease (CAD5)

Autoimmune Hemolytic Anemia | Cold Agglutinin Disease

Finland, Denmark, Norway
Hoag Memorial Hospital Presbyterian
Cancer Biotherapy Research Group

Withdrawn

Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma

Lymphoma

United States
Chronic Lymphocytic Leukemia Research Consortium
Celgene Corporation

Unknown

Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia | CLL | Untreated | First-Line | Front-line | Initial Therapy

United States
Jiang Feng

Recruiting

Neoadjuvant SBRT in Localized Advanced HNSCC

Head and Neck Squamous Carcinoma

China
Merck KGaA, Darmstadt, Germany

Completed

Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects (CHANCE)

Squamous Cell Carcinoma of the Head and Neck

China
Dr. Carl Schimanski

Unknown

FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema (DERMATUX)

Colorectal Cancer Metastatic

Germany
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy

Lung Cancer
Eli Lilly and Company
Bristol-Myers Squibb

Completed

Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy

Colorectal Neoplasms | Neoplasm | Metastases

United States, Canada

Search clinical trials for: Rituximab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations